// App-Quantinova.ai

: Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?

Researchers

Presenter

  • Mona Bafadhel

Principal Investigators

  • Stephen Bourke

  • Chris Compton

  • Gerard Criner

  • Mark Dransfield

  • David Halpin

  • Meilan Han

  • Benjamin Hartley

  • C. Elaine Jones

  • Peter Lange

  • Sally Lettis

  • David Lipson

  • David Lomas

  • Neil Martin

  • Fernando Martinez

  • Ralf Van Der Valk

  • Robert Wise

  • David Singh

Medical Centers

  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom

  • GlaxoSmithKline and Barts and the London School of Medicine and Dentistry, Brentford, Middlesex and London, United Kingdom

  • North Tyneside General Hospital and Newcastle University, North Shields and Newcastle, United Kingdom

  • Glaxo-Smith Kline, Brentford, London, United Kingdom

  • Lewis Katz School of Medicine at Temple University, Philadelpha , United States of America

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Veramed Ltd, Twickenham, United Kingdom,

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • Department of Public Health, University of Copenhagen and Medical Department, Herlev and Gentofte Hospital, Copenhagen and Herlev, Denmark

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GSK and Perelman School of Medicine, University of Pennsylvania, Collegeville and Philadelphia, PA, United States.

  • UCL Respiratory, University College London, London, United Kingdom

  • GlaxoSmithKline and University of Leicester, Brentford and Leicester, United Kingdom

  • NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, United States of America

  • Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, United States of America

  • University of Manchester, Manchester, United Kingdom

Locations

  • United Kingdom

  • United States

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • fluticasone furoate/umeclidinium/vilanterol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02164513

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved